Coley Doubles Toll-Like Receptor Patent Estate With Purchase Of 3M Program
This article was originally published in The Pink Sheet Daily
Executive Summary
$20 million investment also gains the TLR-focused firm a pipeline of small molecule candidates targeting TLR7 and TLR8, as well as a 10,000 compound library.